secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2026-05-12T20:21:32+00:00
Accession:  0001501697-26-000047
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharma shareholders approve 1.5M share equity plan increase, elect three directors at 2026 annual meeting
--------------------------------------------------------------------------------

- Shareholders approved 1,500,000 additional shares under Second Amended and Restated 2017 Equity Incentive Plan.
- Elected Gary Bridger, Françoise De Craecker, and Michael Wyzga as Class III directors until 2029.
- Ratified PricewaterhouseCoopers as independent auditor for fiscal year ending Dec 31, 2026.
- Say-on-pay advisory vote passed with 70.9 million for, 5.4 million against (excluding broker non-votes).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000150169726000047/0001501697-26-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000150169726000047/xfor-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001501697-26-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer